X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs STRIDES SHASUN LTD - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA STRIDES SHASUN LTD ASTRAZENECA PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 91.0 13.8 657.5% View Chart
P/BV x 13.0 1.9 692.4% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
STRIDES SHASUN LTD
Mar-16
ASTRAZENECA PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs1,2851,413 91.0%   
Low Rs634848 74.8%   
Sales per share (Unadj.) Rs189.6353.3 53.7%  
Earnings per share (Unadj.) Rs-0.223.4 -0.9%  
Cash flow per share (Unadj.) Rs3.841.0 9.4%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs68.6320.4 21.4%  
Shares outstanding (eoy) m25.0089.35 28.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.13.2 158.2%   
Avg P/E ratio x-4,712.748.3 -9,750.4%  
P/CF ratio (eoy) x249.627.6 905.1%  
Price / Book Value ratio x14.03.5 396.3%  
Dividend payout %021.4 0.0%   
Avg Mkt Cap Rs m23,988100,988 23.8%   
No. of employees `0001.64.7 33.2%   
Total wages/salary Rs m1,6054,988 32.2%   
Avg. sales/employee Rs Th3,040.26,730.0 45.2%   
Avg. wages/employee Rs Th1,029.21,063.6 96.8%   
Avg. net profit/employee Rs Th-3.3445.5 -0.7%   
INCOME DATA
Net Sales Rs m4,74031,564 15.0%  
Other income Rs m921,212 7.6%   
Total revenues Rs m4,83232,776 14.7%   
Gross profit Rs m-1305,213 -2.5%  
Depreciation Rs m1011,573 6.4%   
Interest Rs m01,803 0.0%   
Profit before tax Rs m-1393,049 -4.6%   
Minority Interest Rs m0127 0.0%   
Prior Period Items Rs m0-27 0.0%   
Extraordinary Inc (Exp) Rs m139-371 -37.4%   
Tax Rs m5689 0.7%   
Profit after tax Rs m-52,089 -0.2%  
Gross profit margin %-2.716.5 -16.6%  
Effective tax rate %-3.722.6 -16.2%   
Net profit margin %-0.16.6 -1.6%  
BALANCE SHEET DATA
Current assets Rs m2,72635,949 7.6%   
Current liabilities Rs m2,43519,402 12.6%   
Net working cap to sales %6.152.4 11.7%  
Current ratio x1.11.9 60.4%  
Inventory Days Days7471 104.0%  
Debtors Days Days41127 32.1%  
Net fixed assets Rs m1,03534,478 3.0%   
Share capital Rs m50894 5.6%   
"Free" reserves Rs m94222,601 4.2%   
Net worth Rs m1,71628,632 6.0%   
Long term debt Rs m027,455 0.0%   
Total assets Rs m4,15676,591 5.4%  
Interest coverage xNM2.7-  
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x1.10.4 276.7%   
Return on assets %-0.15.1 -2.4%  
Return on equity %-0.37.3 -4.1%  
Return on capital %08.2 0.0%  
Exports to sales %5.748.1 11.8%   
Imports to sales %6.514.5 44.7%   
Exports (fob) Rs m27015,192 1.8%   
Imports (cif) Rs m3064,565 6.7%   
Fx inflow Rs m37516,612 2.3%   
Fx outflow Rs m4705,292 8.9%   
Net fx Rs m-9611,320 -0.8%   
CASH FLOW
From Operations Rs m-8717 -1.1%  
From Investments Rs m-146-22,284 0.7%  
From Financial Activity Rs m86229,488 2.9%  
Net Cashflow Rs m7098,073 8.8%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 37.8 0.8%  
FIIs % 15.7 8.6 182.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 25.9 35.1%  
Shareholders   12,856 56,241 22.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 200 Points Higher; Lupin & Axis Bank Top Gainers(09:30 am)

Majority of Asian stock indices are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.07%, while the Hang Seng is up 1.06%.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 22, 2017 10:36 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - WOCKHARDT LTD. COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS